Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lymphomas
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lymphomas
    TopAbstracts in Lymphomas 11/25/2009 - (DGNews)
    TopAbstracts in Lymphomas 11/11/2009 - (DGNews)
    Blood Flow Cytometry May Be Preferable Way to Diagnose, Analyse Mycosis Fungoides: Presented at ASCP - (DGDispatch)
    FDA Approves Romidepsin Injection for Previously Treated T-Cell Lymphoma - (DGNews)
    Immune Therapy Can Protect Against or Treat Later Lymphoma - (DGNews)

    News archive

     Recent webcasts/CME - Lymphomas

    Webcasts/CME archive

     Recent cases - Lymphomas
      Primary Central Nervous System Lymphoma Presenting as Bilateral Uveitis in an Immunocompetent HCV+ Patient: A Case Report
      Primary Malignant Lymphoma of the Ileum Presenting as Intussusception
      Challenging Complications of Treatment - Human Herpes Virus 6 Encephalitis and Pneumonitis in a Patient Undergoing Autologous Stem Cell Transplantation for Relapsed Hodgkin's Disease: A Case Report
      Isolated Hodgkin's Lymphoma of the Oesophagus: A Case Report
      Pulmonary Lymphoma Mimicking Metastases: A Case Report

      Cases archive
        




      my personal edition > lymphomas > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Rituximab Improves Efficacy of Fludarabine-Based Therapy in Chronic Lymphocytic Leukaemia: Presented at NHL

      By Chris Berrie

      PRAGUE, CZECH REPUBLIC -- September 14, 2004 -- The addition of rituximab to fludarabine-based therapy (R-fludarabine) for previously untreated patients with chronic lymphocytic leukaemia (CLL) improves progression-free survival (PFS) and overall survival (OS), according to a historical comparison of 2 multicentre Cancer and Leukaemia Group B studies.

      The results were presented here September 12th at The Role of Immunotherapy in NHL: Optimising Treatment Outcomes, sponsored by Roche, and have just achieved online publication (Byrd et al., Blood, 2004, epub)

      In the absence of relevant prospective randomised studies, and following the update of the results from the randomised CALGB 9712 study of sequential versus concurrent R-fludarabine, Thomas Lin, MD, investigator for CALGB, and assistant professor of internal medicine, division of Haematology and oncology, Ohio State University, Columbus, Ohio, United States, said they recently completed a retrospective comparison of response and survival data of R-fludarabine (CALGB 9712) and fludarabine alone (CALGB 9011).

      In giving the background to CALGB 9712, Dr. Lin indicated that 104 patients had been randomised to the "sequential" or "concurrent" arms. The former consisted of 6 courses of fludarabine 25 mg/m2 on days 1 to 5 every 4 weeks followed by consolidation therapy of rituximab 4 x 375 mg/m2 per week in patients with response or stable disease. The latter was the same, except the patients received additional rituximab 375 mg/m2 on days 1 and 4 of the first cycle, and on day 1 of cycles 2 to 6.

      At a median follow-up of 43 months, the median PFS and OS remained similar between the 2 arms of CALGB 9712, and hence the researchers decided to combine these 104 patients (as R-fludarabine) in this new retrospective analysis with 178 fludarabine-alone patients from CALGB 9001. The patient enrolment criteria and characteristics were comparable between the 2 trials, and there were no significant differences between their demographics and infections.

      Using this historical comparison, R-fludarabine showed a higher incidence of complete response (38% vs 20%; P =.002) and OS (84% vs 63%; P =.0003) when compared with fludarabine alone. Similarly, the 2-year PFS (67% vs 45%; P <.0001) and OS (93% vs 81%; P =.0009) were also significantly better with the rituximab plus fludarabine treatment.

      In concluding, Dr. Lin stressed that although these findings come from a cross-trial analysis, they represent a significant advance in therapy for CLL as they suggest that the addition of rituximab to fludarabine-based therapy significantly improves the complete response, the overall response, progression-free survival, and overall survival, with minimal increased toxicity. Further prospective randomised trials are under way to confirm these findings, he said.


      [Presentation title: Sequential Versus Concurrent Fludarabine and Rituximab in Previously Untreated Chronic Lymphocytic Leukaemia. Abstract 424]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send